Literature DB >> 20564311

Comparative effectiveness research: Policy context, methods development and research infrastructure.

Sean R Tunis1, Joshua Benner, Mark McClellan.   

Abstract

Comparative effectiveness research (CER) has received substantial attention as a potential approach for improving health outcomes while lowering costs of care, and for improving the relevance and quality of clinical and health services research. The Institute of Medicine defines CER as 'the conduct and synthesis of systematic research comparing different interventions and strategies to prevent, diagnose, treat, and monitor health conditions. The purpose of this research is to inform patients, providers, and decision-makers, responding to their expressed needs, about which interventions are most effective for which patients under specific circumstances.' Improving the methods and infrastructure for CER will require sustained attention to the following issues: (1) Meaningful involvement of patients, consumers, clinicians, payers, and policymakers in key phases of CER study design and implementation; (2) Development of methodological 'best practices' for the design of CER studies that reflect decision-maker needs and balance internal validity with relevance, feasibility and timeliness; and (3) Improvements in research infrastructure to enhance the validity and efficiency with which CER studies are implemented. The approach to addressing each of these issues should be informed by the understanding that the primary purpose of CER is to help health care decision makers make informed clinical and health policy decisions. Copyright (c) 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20564311     DOI: 10.1002/sim.3818

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  47 in total

1.  Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.

Authors:  Adam M Huber; Angela B Robinson; Ann M Reed; Leslie Abramson; Sharon Bout-Tabaku; Ruy Carrasco; Megan Curran; Brian M Feldman; Harry Gewanter; Thomas Griffin; Kathleen Haines; Mark F Hoeltzel; Josephine Isgro; Philip Kahn; Bianca Lang; Patti Lawler; Bracha Shaham; Heinrike Schmeling; Rosie Scuccimarri; Michael Shishov; Elizabeth Stringer; Julie Wohrley; Norman T Ilowite; Carol Wallace
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

2.  Comparative effectiveness research in lung diseases and sleep disorders: recommendations from the National Heart, Lung, and Blood Institute workshop.

Authors:  Tracy A Lieu; David Au; Jerry A Krishnan; Marc Moss; Harry Selker; Andrea Harabin; Virginia Taggart; Alfred Connors
Journal:  Am J Respir Crit Care Med       Date:  2011-10-01       Impact factor: 21.405

3.  The European internet-based patient and research database for primary immunodeficiencies: update 2011.

Authors:  B Gathmann; N Binder; S Ehl; G Kindle
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

4.  The landscape of comparative effectiveness research in rheumatology.

Authors:  Esi Morgan DeWitt; Hermine I Brunner
Journal:  Nat Rev Rheumatol       Date:  2013-09-24       Impact factor: 20.543

5.  Epidemiology, comparative effectiveness research, and the National Institutes of Health: forces for health.

Authors:  Michael S Lauer; Richard Hodes
Journal:  Epidemiology       Date:  2011-09       Impact factor: 4.822

6.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

7.  Relative effectiveness and the European pharmaceutical market.

Authors:  Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2011-04

8.  Added value of cost-utility analysis in simple diagnostic studies of accuracy: (18)F-fluoromethylcholine PET/CT in prostate cancer staging.

Authors:  Oke Gerke; Mads H Poulsen; Poul Flemming Høilund-Carlsen
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

9.  What can comparative effectiveness research contribute to integrative health in international perspective?

Authors:  Claudia M Witt; Shelly Rafferty Withers; Suzanne Grant; Michael S Lauer; Sean Tunis; Brian M Berman
Journal:  J Altern Complement Med       Date:  2014-11-05       Impact factor: 2.579

Review 10.  Comparative effectiveness research in the "real" world: lessons learned in a study of treatment-resistant hypertension.

Authors:  Marilyn A Laken; Rosalind Dawson; Otis Engelman; Oscar Lovelace; Charles Way; Brent M Egan
Journal:  J Am Soc Hypertens       Date:  2013 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.